Browsing by Publisher "Turkish Society of Hematology"

Now showing 1 - 10 of 10
  • No Thumbnail Available
    Item
    Treatment of intrathecal methotrexate overdose with folinic acid rescue and lumbar cerebrospinal fluid exchange: A report of two cases; [Yüksek doz intratekal metotreksat'ın folinik asit ve beyin omurilik sıvısı deg̈işimi ile tedavisi: Ïki olgu sunumu]
    (Turkish Society of Hematology, 2011) Kazanci E.; Gülen H.; Erbay A.; Vergin C.
    We report two male cases (4- and 5-years-old) of intrathecal methotrexate overdose. The two boys with acute lymphoblastic leukemia were to receive intrathecal injection of methotrexate. Instead of the prescribed 12 mg, they both received a dose of 120 mg. The initial cerebrospinal fluid samples showed methotrexate concentration of 2.24×10-2M in case 1 and 1.32×10-2M in case 2. The cases were successfully treated with cerebrospinal fluid (CSF) exchange and intravenous folinic acid rescue. The favorable outcome in our cases suggests that CSF exchange is safe and that folinic acid rescue may be adequate to prevent sequelae in patients subjected to intrathecal MTX overdoses up to 120 mg. We propose CSF exchange and intravenous folinic acid as the mainstay of treatment. In addition to the staff 's failure to check the drug label carefully, the marked resemblance of the two dose preparations of MTX may have been contributory.
  • No Thumbnail Available
    Item
    From bone marrow necrosis to gaucher disease; a long way to run; [Kemik İliği Nekrozundan Gaucher Hastalığı Tanısına Uzun Yol]
    (Turkish Society of Hematology, 2015) Erdem N.; Çizmecioğlu A.; Aydoğdu İ.
    [No abstract available]
  • No Thumbnail Available
    Item
    The effect of FcγRIIIA gene polymorphism on the treatment of diffuse large B-cell non-hodgkin lymphoma: A multicenter prospective observational study; [FcgRIIIA gen polimorfizminin diffüz büyük b hücreli non-hodgkin lenfoma tedavisine etkisi: Çok merkezli prospektif gözlemsel Çalışma]
    (Turkish Society of Hematology, 2015) Büyükkurt N.; Özcan M.A.; Ergene Ü.; Payzın B.; Tunalı S.; Demirkan F.; Özsan H.; Pişkin Ö.; Ündar B.
    Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the FcgRIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of FcgRIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS). Materials and Methods: Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positive DLBCL were enrolled in the study. The single nucleotide polymorphisms of the FcgRIIIA gene were analyzed by real time- PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, the patients were clinically and radiologically evaluated for disease status every 3 months. Results: Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of FcgRIIIA were 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. The patients’ oRR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish any statistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F, V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower than in the other 2 allele groups (p=0.01). Conclusion: The distribution of gene polymorphisms in our study group was similar to those of previous studies. While oRR was similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of FcgRIIIA. © 2015, Turkish Society of Hematology. All rights reserved.
  • No Thumbnail Available
    Item
    24th EADV congress; [24. EADV kongresi]
    (Turkish Society of Hematology, 2015) Ermertcan A.T.
    [No abstract available]
  • No Thumbnail Available
    Item
    Serum zinc levels in iron deficient women: A case-control study; [Demir eksikliği anemisi olan kadınlarda serum çinko seviyesinin değerlendirilmesi: Olgu kontrol çalışması]
    (Turkish Society of Hematology, 2016) Özhan O.; Erdem N.; Aydoğdu İ.; Erkurt A.; Kuku İ.
    Since similar symptoms and findings can be seen in the deficiencies of both iron and zinc, we aimed to evaluate the serum zinc levels of women with iron deficiency anemia (IDA). This study was conducted with women with iron deficiency and a healthy control group. When serum zinc levels were compared, they were found to be lower in the IDA group, which was statistically significant. With the help of these studies, iron and zinc treatment instead of only iron replacement may be considered in cases of iron deficiency. © 2016, Turkish Society of Hematology. All rights reserved.
  • No Thumbnail Available
    Item
    Pathological fracture in odontoid process in multiple myeloma; [Multipl miyelom tanılı hastada saptanan patolojik odontoid kırığı]
    (Turkish Society of Hematology, 2017) Acar E.A.; Demirci U.; Pabuşçu Y.; Miskioğlu H.M.; Aydoğdu İ.
    [No abstract available]
  • No Thumbnail Available
    Item
    The diagnostic value of lesional skin smears performed by experienced specialist in cutaneous leishmaniasis and routine microbiology laboratory; [Kutanöz Leishmaniasiste Deneyimli Uzman ve Rutin Mikrobiyoloji Laboratuvarı Tarafından Yapılan Lezyonal Yaymaların Tanısal Değeri]
    (Turkish Society of Hematology, 2019) An İ.; Harman M.; Çavuş İ.; Özbilgin A.
    Objective: Leishmaniasis is a common vector-borne infection affecting 12 million people in 98 countries. The most frequently used method in diagnosis is the microscopic investigation of the leishmania smears. The diagnostic value of this method varies according to the experience of the evaluator. In this prospective study, it was aimed to emphasize the importance of experience in the evaluation of lesional smears used in the diagnosis of cutaneous leishmaniasis. Methods: In this study, patients who were admitted to Dicle University Medical Faculty Hospital Dermatological and Venereal Diseases Outpatient Clinic between January and December 2016 and who had lesions with suspicious cutaneous leishmaniasis were included. For all the cases, both in the routine microbiology laboratory and in the diagnosis and treatment of cutaneous leishmaniasis, separate smears were performed by an experienced specialist and evaluated independently from each other. Results: In 70 of 98 cases studied, the diagnosis of cutaneous leishmaniasis was confirmed by laboratory evaluations. The rate of positivity was significantly higher in the smears analyzed by experienced specialist in the clinical and diagnosis of cutaneous leishmaniasis (95.7%) than in the smears analyzed by the routine microbiology laboratory (42.9%) (p<0.001). Conclusion: The data in our study showed that smears should be performed and evaluated by experienced specialists in the clinical and diagnosis of cutaneous leishmaniasis. © Telif Hakkı 2019 Türk Dermatoloji Derneği.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data; [Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi]
    (Turkish Society of Hematology, 2021) Tombak A.; Tanrıkulu F.P.; Durusoy S.S.; Dinçyürek H.D.; Kaya E.; Ümit E.G.; Yavaşoğlu İ.; Mehtap Ö.; Deveci B.; Özcan M.A.; Terzi H.; Okay M.; Sayınalp N.; Yılmaz M.; Okan V.; Kızıklı A.; Özcan Ö.; Çetin G.; Demircioğlu S.; Aydoğdu İ.; Saydam G.; Davulcu E.A.; İlhan G.; Uçar M.A.; Özet G.; Akpınar S.; Turgut B.; Berber İ.; Kurtoğlu E.; Sönmez M.; Batur D.S.; Yıldırım R.; Özkocamaz V.; Güneş A.K.; Sahip B.; Ertop Ş.; Akay O.M.; Baştürk A.; Doğu M.H.; Akdeniz A.; Ünal A.; Seyhanlı A.; Gürkan E.; Çekdemir D.; Ferhanoğlu B.
    Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age ± standard deviation: 64.6±10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes. © 2021 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.
  • No Thumbnail Available
    Item
    Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study; [Çocuklarda Sistemik Rekombinant Doku Plazminojen Aktivatörü ile Tromboliz: Çok Merkezli Bir Retrospektif Çalışma]
    (Turkish Society of Hematology, 2021) Zengin E.; Sarper N.; Erdem A.Y.; Al I.O.; Evim M.S.; Yaralı N.; Belen B.; Akçay A.; Yıldırım A.T.; Karapınar T.H.; Güneş A.M.; Gelen S.A.; Ören H.; Olcay L.; Baytan B.; Gülen H.; Öztürk G.; Orhan M.F.; Oymak Y.; Akpınar S.; Tüfekçi Ö.; Albayrak M.; Güneş B.T.; Canpolat A.; Özbek N.
    Objective: This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA). Materials and Methods: Retrospective data were collected from 13 Turkish pediatric hematology centers. The dose and duration of rtPA treatment, concomitant anticoagulant treatment, complete clot resolution (CCR), partial clot resolution (PCR), and bleeding complications were evaluated. Low-dose (LD) rtPA treatment was defined as 0.01-0.06 mg/kg/h and high-dose (HD) rtPA as 0.1-0.5 mg/kg/h. Results: Between 2005 and 2019, 55 thrombotic episodes of 54 pediatric patients with a median age of 5 years (range: 1 day to 17.75 years) were evaluated. These patients had intracardiac thrombosis (n=16), deep vein thrombosis (DVT) (n=15), non-stroke arterial thrombosis (n=14), pulmonary thromboembolism (PE) (n=6), and stroke (n=4). The duration from thrombus detection to rtPA initiation was a median of 12 h (range: 2-504 h) and it was significantly longer in cases of DVT and PE compared to stroke, non-stroke arterial thrombosis, and intracardiac thrombosis (p=0.024). In 63.6% of the episodes, heparin was initiated before rtPA treatment. LD and HD rtPA were administered in 22 and 33 of the episodes, respectively. Concomitant anticoagulation was used in 90% and 36% of the episodes with LD and HD rtPA, respectively (p=0.0001). Median total duration of LD and HD rtPA infusions was 30 h (range: 2-120 h) and 18 h (2-120 h), respectively (p=0.044). Non-fatal major and minor bleeding rates were 12.5% and 16.7% for LD and 3.2% and 25.8% for HD rtPA, respectively. At the end of the rtPA infusions, CCR and PCR were achieved in 32.7% and 49.0% of the episodes, respectively. The most successful site for thrombolysis was intracardiac thrombosis. HD versus LD rtPA administration was not correlated with CCR/PCR or bleeding (p>0.05). Conclusion: Systemic thrombolytic therapy may save lives and organs effectively if it is used at the right indications and the right times in children with high-risk thrombosis by experienced hematologists with close monitoring of recanalization and bleeding. © 2021, Turkish Society of Hematology. All rights reserved.
  • No Thumbnail Available
    Item
    Cutaneous anaplastic large-cell lymphoma with dramatic response to brentuximab vedotin; [Brentuximab vedotine dramatik yanıtlı kutanöz anaplastik büyük hücreli lenfoma]
    (Turkish Society of Hematology, 2021) Şahin M.; Miskioğlu M.; Inanır I.; Akar H.; Neşe N.; Temiz P.; Aydoğdu İ.
    [No abstract available]